Skip to main content
. Author manuscript; available in PMC: 2011 Dec 15.
Published in final edited form as: Cancer Res. 2010 Dec 15;70(24):10310–10320. doi: 10.1158/0008-5472.CAN-10-2062

Figure 7. p53 mutant cells are susceptible to transient treatment with MLN4924.

Figure 7

(A) HCT116 WT, p53−/− or p21−/− cells were treated with 0, 0.1, 0.3, 0.9, 1.8 or 2.7μM of MLN4924. Cell survival rates were measured as described in Figure 6(B). Mean and standard deviation from triplicates. * indicates statistical significance (p<0.01). (B) Viable HCT116, MCF7 (MLN4924 treatment 24hrs after control or p53 siRNA), H460 and H23 cells after 8hr MLN4924 treatment at different doses were measured using MTT assay as described. The points indicate mean and standard deviation of triplicates. * indicates statistically significant difference at various MLN4924 concentrations between the two cell lines (p<0.01).